Print

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/114/pembrolizumab-plus-lenvatinib-versus-chemotherapy-for-endometrial-cancer

Clinicaltrials.gov identifier:
NCT03884101 (https://clinicaltrials.gov/show/NCT03884101)


Study Contact Information:

For additional information, please contact: 1-888-577-8839 or [email protected]


About the Study

The purpose of this study is to compare the effectiveness of using a combination of the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy lenvatinib (Lenvima) in women with Stage III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment.

Type of Study

This is a 2-arm, randomized, open-label, phase 3 study.  


What the Study Entails

Follow up


Study Sites

Alabama Arizona California Colorado Connecticut
Georgia Louisiana Maine Minnesota New Jersey
New York North Carolina North Dakota Oregon South Dakota
Texas Washington      

 

Alabama

Arizona

California

Colorado

Connecticut

Georgia

Louisiana

Maine

Minnesota

New Jersey

New York

North Carolina

North Dakota

Oregon

South Dakota

Texas

Washington


This Study is Open To:

NOTE: This study has completed enrollment.

This Study is Not Open To:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.